Adaptimmune gets endorsement for dose escalation in ADP-A2AFP study

Adaptimmune announced that the Safety Review Committee, or SRC, has endorsed dose escalation in the ongoing ADP-A2AFP study in patients with hepatocellular carcinoma to the second dose cohort. The SRC has also endorsed moving to the expansion phase of the ADP-A2M10 lung cancer study. Across both studies, most adverse events have been consistent with those typically experienced by cancer patients undergoing cytotoxic chemotherapy or other cancer immunotherapies with no evidence of alloreactivity or toxicity related to off-target binding. In the ADP-A2AFP study, two patients have received 100M transduced SPEAR T-cells targeting AFP in the first dose cohort, and there was no evidence of hepatotoxicity. The SRC endorsed dose escalation after evaluating the first two patients and taking into consideration the benefit:risk profile observed across programs in Cohort 1. In the ADP-A2M10 lung cancer study, ten patients have been treated in the first three cohorts and the expansion phase will allow for doses of up to 10B transduced cells.

https://thefly.com/landingPageNews.php?id=2844427